The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
Open accessPublished version of a preprint
Abstract
SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · cited 3×
“The ease of naturally elicited Abs to recognize the S might be associated with the low rate of somatic hypermutation observed in neutralizing Abs.(9) This low somatic hypermutation rate could in turn explain why most SARS-CoV-2-infected individuals are able to generate neutralizing Abswithin only 2weeks after infectio…”
InfluentialRapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19
Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2025179 · Cited by 1,021
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
Zang, R., Castro, M. F. G., McCune, B. T., Zeng, Q., Rothlauf, P. W., Sonnek, N. M., Liu, Z., Brulois, K. F., Wang, X., Greenberg, H. B., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc3582 · Cited by 982
Self-citationUnexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582
Research works printed but not linked: 25
- Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Yuan, 2020, A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV, Science, 368, 630, 10.1126/science.abb7269 · DOI · Paper page
- Shi, 2020, A human neutralizing antibody targets the receptor binding site of SARS-CoV-2, Nature, 584, 120, 10.1038/s41586-020-2381-y · DOI · Paper page
- Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241 · DOI · Paper page
- Murin, 2019, Antibody responses to viral infections: a structural perspective across three different enveloped viruses, Nat. Microbiol., 4, 734, 10.1038/s41564-019-0392-y · DOI · Paper page
- Rouse, 2010, Immunity and immunopathology to viruses: what decides the outcome?, Nat. Rev. Immunol., 10, 514, 10.1038/nri2802 · DOI · Paper page
- Stadlbauer, 2020, SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup, Curr. Protoc. Microbiol., 57, e100, 10.1002/cpmc.100 · DOI · Paper page
- Grzelak, 2020, SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors, medRxiv
- Jaimes, 2020, Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop, J. Mol. Biol., 432, 3309, 10.1016/j.jmb.2020.04.009 · DOI · Paper page
- Zhou, 2020, A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein, Curr. Biol., 30, 2196, 10.1016/j.cub.2020.05.023 · DOI · Paper page
- Madu, 2009, Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide, J. Virol., 83, 7411, 10.1128/JVI.00079-09 · DOI · Paper page
- Sterlin, 2020, IgA dominates the early neutralizing antibody response to SARS-CoV-2, medRxiv
- Watanabe, 2020, Site-specific glycan analysis of the SARS-CoV-2 spike, Science, 369, 330, 10.1126/science.abb9983 · DOI · Paper page
- Watanabe, 2020, Vulnerabilities in coronavirus glycan shields despite extensive glycosylation, Nat. Commun., 11, 2688, 10.1038/s41467-020-16567-0 · DOI · Paper page
- Sok, 2018, Recent progress in broadly neutralizing antibodies to HIV, Nat. Immunol., 19, 1179, 10.1038/s41590-018-0235-7 · DOI · Paper page
- Yin, 2020, Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient, J. Infect., 81, e31, 10.1016/j.jinf.2020.06.076 · DOI
- Zhang, 2020, Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019, J. Infect. Dis., 222, 183, 10.1093/infdis/jiaa229 · DOI
- Perreault, 2020, Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within four months after symptom onset, Blood, 10.1182/blood.2020008367 · DOI
- Hofmann, 2005, Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry, Proc. Natl. Acad. Sci. USA, 102, 7988, 10.1073/pnas.0409465102 · DOI · Paper page
- Hoffmann, 2013, Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses, PLoS One, 8, e72942, 10.1371/journal.pone.0072942 · DOI
- Lodge, 1997, The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells, EMBO J., 16, 695, 10.1093/emboj/16.4.695 · DOI · Paper page
- Liu, 2013, The interferon-inducible MxB protein inhibits HIV-1 infection, Cell Host Microbe, 14, 398, 10.1016/j.chom.2013.08.015 · DOI · Paper page
- ter Meulen, 2006, Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med., 3, e237, 10.1371/journal.pmed.0030237 · DOI · Paper page
- Tian, 2020, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerg. Microbes Infect., 9, 382, 10.1080/22221751.2020.1729069 · DOI · Paper page
- Desforges, 2013, The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus, J. Virol., 87, 3097, 10.1128/JVI.02699-12 · DOI
Cited by
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Song, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23074-3 · Cited by 285
Tan, T. K., Rijal, P., Rahikainen, R., Keeble, A. H., Schimanski, L., Hussain, S., Harvey, R., Hayes, J. W. P., Edwards, J. C., McLean, R. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20654-7 · Cited by 283
Metadata
- Authors
- Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., Medjahed, H., Lewin, A., Perreault, J., Tremblay, T., Gendron-Lepage, G., Gauthier, N., Carrier, M., Marcoux, D., Piché, A., Lavoie, M., Benoit, A., Loungnarath, V., Brochu, G., Haddad, E., Stacey, H. D., Miller, M. S., Desforges, M., Talbot, P. J., Maule, G. T. G., Côté, M., Therrien, C., Serhir, B., Bazin, R., Roger, M., & Finzi, A.
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 1
- Issue
- 7
- Pages
- 100126
- ISSN
- 2666-3791 (ISSN-L)
- OpenAlex
- W3090857960
- Cited by
- 206
- References
- 12
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Canadian Institutes of Health Research
- Fondation du CHUM
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. https://app.cochat.ai/papers/10.1016/j.xcrm.2020.100126
- The paper
- Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., Medjahed, H., Lewin, A., Perreault, J., Tremblay, T., Gendron-Lepage, G., Gauthier, N., Carrier, M., Marcoux, D., Piché, A., . . . Finzi, A. (2020). Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2020.100126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.